文献速递糖尿病肥胖与代谢综合征

儿童肥胖中pFIB评分与青年起病2型糖尿病风险相关

pFIB scores for paediatric MASLD fibrosis are associated with risk of youth-onset type 2 diabetes in children with obesity.
PubMed 文献 · Diabetologia · 2026-07-22

基于瑞典儿童肥胖治疗登记(BORIS,2005-2020)的队列研究纳入4856名肥胖儿童和23758名一般人群对照,评估儿科肝纤维化风险评分pFIB-c和pFIB-6对青年起病2型糖尿病的预测价值。结果显示,在肥胖儿童中,pFIB-6≥4者占12.4%,其9-19岁发生2型糖尿病的风险显著增加(校正HR 3.05,95%CI 2.17-4.28),但两评分对20-25岁发病无预测作用。

要点

  • 肥胖儿童中pFIB-6≥4者短期2型糖尿病风险增加约3倍。
  • pFIB评分对20-25岁发病无预测价值。
  • ALT和HOMA-IR是与2型糖尿病风险关联最强的组分。

核心结论

  • 肝源性复合风险评分可识别短期2型糖尿病风险显著增高的肥胖青少年亚组。
  • 整合肝脏和代谢变量可能改善儿童肥胖的早期风险分层。

研究设计与样本

  • 队列研究,使用瑞典儿童肥胖治疗登记(BORIS,2005-2020)链接国家登记,纳入4856名肥胖儿童(基线年龄12.0岁)和23758名一般人群对照。
  • 采用Cox回归和灵活参数生存模型进行时间-事件分析,计算HR。

主要发现

  • 肥胖儿童中12.4%的pFIB-6≥4。
  • 高pFIB-6评分增加9-19岁发生2型糖尿病的风险(校正HR 3.05 [95% CI 2.17, 4.28])。
  • 每10000人年发病率(95% CI):一般人群对照1.02(0.61, 1.72),肥胖且pFIB-6<4者45.5(37.8, 54.7),pFIB-6≥4者161.7(122.2, 213.9)。
  • 两个评分在儿科年龄测量时均不能预测20-25岁发生2型糖尿病的风险。
  • 在评分组分中,升高的丙氨酸氨基转移酶(ALT)和HOMA-IR与2型糖尿病风险关联最强。

临床怎么用

  • 对于肥胖儿童,可计算pFIB-6评分识别短期2型糖尿病高风险个体。
  • 对pFIB-6≥4的肥胖青少年,考虑在青春期加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Youth-onset type 2 diabetes is an aggressive phenotype of metabolic disease, yet tools to identify children with obesity at highest short-term risk are limited. We evaluated whether the paediatric liver fibrosis risk scores (pFIB) pFIB-c and pFIB-6, originally developed for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis risk stratification, identify individuals at increased risk of incident type 2 diabetes. METHODS: A cohort study was conducted using the Swedish Childhood Obesity Treatment Register (BORIS, 2005-2020) linked with national registers, from which type 2 diabetes was ascertained. We included 4856 children with obesity (aged 12.0 years at baseline) and 23,758 general population comparators. The pFIB-c and pFIB-6 scores were calculated as published. Time-to-event analysis yielding HR was performed using Cox regression and flexible parametric survival models. RESULTS: Among children with obesity, 12.4% had a pFIB-6 ≥4. A high pFIB-6 score increased the risk for type 2 diabetes at 9-19 years of age (adjusted HR 3.05 [95% CI 2.17, 4.28]). The incidence rate (95% CI) per 10,000 person-years was 1.02 (0.61, 1.72) in the general population comparators, 45.5 (37.8, 54.7) in individuals with obesity and a pFIB-6 <4, and 161.7 (122.2, 213.9) when the pFIB-6 was ≥4. In contrast, neither score, measured at paediatric age, predicted type 2 diabetes risk at 20-25 years of age. Among individual score components, elevated alanine aminotransferase (ALT) and HOMA-IR were most strongly associated with type 2 diabetes risk. In an independent cohort, higher pFIB-6 scores were associated with greater adipose tissue insulin resistance. CONCLUSIONS/INTERPRETATION: A liver-derived composite risk score identifies a subgroup of adolescents with obesity at markedly increased short-term risk of type 2 diabetes. These findings suggest that integrating hepatic and metabolic variables may improve early risk stratification in paediatric obesity and help identify individuals who may benefit from intensified monitoring during adolescence.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Lefere S, Putri RR, Danielsson P, et al. pFIB scores for paediatric MASLD fibrosis are associated with risk of youth-onset type 2 diabetes in children with obesity. Diabetologia. 2026. PMID: 42486926. doi:10.1007/s00125-026-06804-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。